Skip to main content
BiotoxtechCo.,Ltd. logo

BiotoxtechCo.,Ltd. — Investor Relations & Filings

Ticker · 086040 ISIN · KR7086040003 KO Professional, scientific and technical activities
Open in API
Filings indexed 172 across all filing types
Latest filing 2020-02-27 Proxy Solicitation & In…
Country KR South Korea
Listing KO 086040

About BiotoxtechCo.,Ltd.

http://eng.biotoxtech.com/

Biotoxtech Co., Ltd. is a non-clinical Contract Research Organization (CRO) that provides safety and efficacy evaluation services. The company offers a comprehensive suite of GLP-compliant studies, including general toxicity, carcinogenicity, reproductive and developmental toxicity, genotoxicity, immunotoxicity, and safety pharmacology. It also conducts efficacy evaluations and provides analytical research services such as pharmacokinetics (PK/TK/ADME) and bioanalysis. Biotoxtech serves a diverse clientele developing pharmaceuticals, biomedicines, cell and gene therapies, medical devices, chemicals, agrochemicals, cosmetics, and health functional foods.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Biotoxtech. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors and auditors, and remuneration limits. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and agenda items.
2020-02-27 Korean
[첨부추가]타법인주식및출자증권처분결정
M&A Activity Classification · 1% confidence The document is a regulatory filing from Biotoxtech regarding the 'Disposal of Shares and Securities of Other Corporations' (타법인주식및출자증권처분결정). It details the sale of shares in BioMix, the transaction amount, the purpose (settlement of a legal dispute/reconciliation recommendation), and the board's decision date. This is a standard corporate disclosure of a material transaction, which falls under the 'Regulatory Filings' category as it is a specific corporate event announcement that does not fit into more specialized categories like M&A or Share Issuance.
2020-01-17 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain the full report or financial statements, but rather serves as a formal notice of a corporate action. Given it is a regulatory announcement that does not fit into specific categories like dividend or share buyback, it falls under the general regulatory filing category.
2019-12-16 Korean
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the 3rd quarter of the 20th fiscal year (2019.01.01-2019.09.30) for Biotoxtech Co., Ltd. It contains detailed financial statements, business descriptions, management analysis, and governance information, which are characteristic of a comprehensive interim/quarterly report rather than a simple announcement or summary. 9M 2019
2019-11-14 Korean
기타경영사항(특허권취득)(자율공시)(하이드로퀴논 유도체를 포함하는 비만 또는 비알콜성지방간염의 예방 및 치료용 약학 조성물)
Regulatory Filings Classification · 1% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent by Biotoxtech. It details the patent name, content, and utilization plan. Since this is a specific corporate announcement regarding a business development (patent acquisition) that does not fit into financial reporting, governance, or shareholder meeting categories, it falls under the general regulatory filing category.
2019-08-20 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '주식회사 바이오톡스텍' covering the period from 2019.01.01 to 2019.06.30. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2019
2019-08-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.